Evolve Neuro wants to diagnose ADHD in the time it takes to brew a cup of tea. That's the promise, anyway—five minutes of electroencephalography readings, run through proprietary algorithms, yielding insights that typically take months or years to obtain through Britain's overstretched health system.
The London-based startup launched its Nura Scan assessment publicly in late April 2026, pitching it as an answer to one of the UK's most stubborn healthcare problems. NHS wait times for ADHD evaluations routinely stretch past a year, sometimes two. Private pathways exist but cost hundreds or thousands of pounds, according to patient advocacy groups tracking the market. Somewhere in that gap, Evolve's founders see an opening.
Whether they're right is another question entirely.
Pete O'Mara-Kane, the company's CEO, and Dr. Michael Keane, a neuroscientist serving as chief science officer, have built their bet around EEG—brain wave monitoring via scalp electrodes—married to machine learning. It's not a novel approach. The U.S. Food and Drug Administration cleared NEBA Health's theta-beta ratio tool back in 2013 for pediatric ADHD assessment. But Evolve is aiming broader: adults, not just children. Wellness checks, not just clinical diagnostics. A market that legacy neurodiagnostic platforms haven't quite figured out how to crack.
The ambition shows in the company's pricing architecture. Packages start at €19 per month—positioned as corporate wellness tools—and climb to €20,000 for "Pro" offerings that appear aimed at sports teams and enterprise clients. The website namedrops Premier League clubs and Olympic athletes, though these references remain marketing claims rather than case studies anyone can verify. (The company didn't respond to requests for specifics.)
Speed Meets Skepticism
Nura Scan investigates more than 30 cognitive, clinical, and behavioral markers, according to an April 2026 product listing. The system promises results in five minutes, though the company's LinkedIn profile still references a "10-minute" assessment—a minor inconsistency, perhaps, but the kind of detail that suggests a startup still refining its pitch.
The bigger question is clinical validity. Evolve's website doesn't mention CE marking or FDA clearance as of mid-2026. No peer-reviewed studies back the platform's diagnostic claims. The scientific literature offers cautious optimism about AI-driven EEG analysis for ADHD, with research from recent years exploring classification pipelines, but most of that work remains in the lab. Older systematic reviews have warned that EEG biomarkers alone—theta-beta ratios, for instance—aren't sufficient for diagnosis.
Evolve's proprietary approach may sidestep those limitations. Or it may not. Without published validation, it's hard to say.
The competitive landscape is crowded and technically varied. Qbtech's QbTest, which combines continuous performance testing with motion tracking (no EEG involved), has earned NICE medtech guidance in the UK—a stamp of credibility Evolve hasn't yet secured. Firefly Neuroscience has been vocal this year about EEG-based biomarkers for ADHD subtypes, issuing research updates as recently as spring 2026. BlinkLab is pursuing smartphone-based sensory assessments and announced a European partnership for ADHD diagnostics back in mid-2024.
None of these companies has broken through to mainstream adoption. The question is whether anyone can.
A Dual Identity Problem
Part of Evolve's challenge is strategic: the company straddles wellness and diagnostics, two markets with very different regulatory expectations. Selling brain scans to corporate wellness programs is one thing. Offering them as clinical screening tools is another, inviting scrutiny from regulators who don't tend to look kindly on medical claims unsupported by evidence.
The company's funding base is modest. Evolve Neuro—legally registered as Replikate Neuro, an Irish entity established in 2022 with a UK arm opened in December 2023—raised £190,000 in a seed round from SFC Capital in June 2024. Investor databases suggest total funding to date sits between £250,000 and £500,000, with SFC Capital the only named backer. LinkedIn pegs the team size at 11 to 50 employees, spread across offices in London, Dublin, and New York.
That's a lean operation navigating a complex path: product iteration, clinical validation, regulatory approval, market education. All while trying to stand out in a field where claims of breakthrough diagnostics are common and evidence is often thin.
What Comes Next
The NHS ADHD backlog isn't going anywhere soon. Scottish Parliament briefings from mid-2025 and neurodiversity advocacy sites updated as recently as early 2026 document assessment delays that stretch across UK trusts—multi-month waits at best, multi-year at worst. Private diagnostic services have proliferated in response, but they're expensive and inconsistently standardized. Digital tools offering faster, cheaper screening could theoretically compress both timelines and costs.
If they work.
For Evolve, the next chapter depends on data. Peer-reviewed studies. Real-world evidence showing Nura Scan does what it claims. Regulatory approvals that transform a fast test into a trusted one. Right now, the company's positioning blends performance optimization, wellness checks, and diagnostic screening—a hedge, maybe, against an uncertain path forward. But that duality complicates reimbursement prospects and institutional adoption.
Speed matters in diagnostics. So does trust. Evolve Neuro has the former down to five minutes. The latter may take considerably longer.
